Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 26

Sort by

Sort Order Select

Journal Articles

Final Clinical Results with Laboratory Correlates in the Phase I Trial of Lenalidomide Plus Plerixafor in Previously Treated Chronic Lymphocytic Leukemia (CLL)

Danielle M. Brander, MD, Sallie D. Allgood, MS, David A. Rizzieri, MD, Tiffany Stewart, BS, J. Brice Weinberg, MD, Mark C Lanasa, MD PhD

Blood (2014) 124 (21): 5658.

https://doi.org/10.1182/blood.V124.21.5658.5658

Published: 2014

Journal Articles

Molecular and Clinical Associations Between Vitamin D and Chronic Lymphocytic Leukemia

Nina Beri, MD, Daphne R. Friedman, MD, Tiffany M. Simms, BS, Maragatha Kuchibhatla, PhD, J. Brice Weinberg, MD, Mark C. Lanasa, MD, PhD

Blood (2013) 122 (21): 5282.

https://doi.org/10.1182/blood.V122.21.5282.5282

Published: 2013

Journal Articles

Next-Generation Sequencing Reveals Oncogenic Driver Mutations In Both Progressive and Non-Progressive Monoclonal B Lymphocytosis

Mark C. Lanasa, MD, PhD, Doreen te Raa, MD, Sallie D. Allgood, MS, Paula Scotland, PhD, Cassie Love, MS, Zhen Sun, MS, Arend Jan van Houte, PhD, Douwe Biesma, MD, PhD, Arnon P. Kater, MD PhD, Sandeep Dave, MD

Blood (2013) 122 (21): 1615.

https://doi.org/10.1182/blood.V122.21.1615.1615

Published: 2013

Journal Articles

First-In-Human Study Of AMG 319, a Highly Selective, Small Molecule Inhibitor Of PI3Kδ, In Adult Patients With Relapsed Or Refractory Lymphoid Malignancies

Mark C. Lanasa, MD, PhD, Martha Glenn, MD, Anthony R. Mato, MD, Sallie D. Allgood, MS, Susan Wong, Benny Amore, Gary Means, Erin Stevens, Chris Yan, Gregory Friberg, Andre Goy, MD

Blood (2013) 122 (21): 678.

https://doi.org/10.1182/blood.V122.21.678.678

Published: 2013

Journal Articles

What Numbers Don't Say: Immunogenetic Evidence Shows That High-Count MBL Resembles Rai 0 CLL While Low-Count MBL Does Not.

Anna Vardi, Antonis Dagklis, Lydia Scarfò, Diane F. Jelinek, PhD, Darren J Newton, Chi Doughty, PhD, Julia Almeida, Arancha Rodriguez-Caballero, Sallie D. Allgood, MS, Mark C. Lanasa, MD, PhD, Agostino Cortelezzi, MD, Ester M Orlandi, Silvio Veronese, Marco Montillo, MD, Andy Rawstron, PhD, Tait D. Shanafelt, MD, Alberto Orfao, Kostas Stamatopoulos, Paolo Ghia

Blood (2012) 120 (21): 2883.

https://doi.org/10.1182/blood.V120.21.2883.2883

Published: 2012

Journal Articles

The Relationship Between Socioeconomic Status and Clinical Outcomes in African Americans with Chronic Lymphocytic Leukemia

Catherine C Coombs, MD, J. Brice Weinberg, MD, Mark C. Lanasa, MD, PhD

Blood (2012) 120 (21): 3912.

https://doi.org/10.1182/blood.V120.21.3912.3912

Published: 2012

Journal Articles

Comparison of the PI3K-δ Inhibitors TGR1202 and GS-1101 in Inducing Cytotoxicity and Inhibiting Phosphorylation of Akt in CLL Cells in Vitro

Daphne R. Friedman, M.D., Mark C. Lanasa, MD, PhD, Danielle M. Brander, MD, Sallie D. Allgood, MS, Evan D. Davis, BS, Hari Miskin, Srikant Viswanadha, Swaroop Vakkalanka, J. Brice Weinberg, MD

Blood (2012) 120 (21): 3914.

https://doi.org/10.1182/blood.V120.21.3914.3914

Published: 2012

Journal Articles

Circulating B Cell Clones in Familial Waldenström Macroglobulinemia.

Mark C. Lanasa, MD, PhD, Sallie D. Allgood, MS, Lynn R. Goldin, PhD, Danielle M. Brander, MD, Mary L. McMaster, MD

Blood (2012) 120 (21): 2703.

https://doi.org/10.1182/blood.V120.21.2703.2703

Published: 2012

Journal Articles

Race As a Determinant of Disease Biology and Outcomes in Chronic Lymphocytic Leukemia

Catherine C Coombs, MD, Laura Z. Rassenti, Ph.D., Susan L Slager, PhD, Sara Strom, PhD, J. Brice Weinberg, MD, Thomas J Kipps, MD, PhD, Mark C Lanasa, MD, PhD

Blood (2011) 118 (21): 1785.

https://doi.org/10.1182/blood.V118.21.1785.1785

Published: 2011

Journal Articles

Phase 1 Study of TRU-016, An Anti-CD37 SMIP™ Protein in Relapsed and/or Refractory NHL Patients

John M. Pagel, MD, PhD, Stephen Spurgeon, MD, Farrukh Awan, MD, MS, Kristie A. Blum, MD, Mark C Lanasa, MD, PhD, Ian W. Flinn, MD, PhD, Scott Stromatt, MD, John C. Byrd, MD, Ajay K. Gopal, MD

Blood (2011) 118 (21): 1636.

https://doi.org/10.1182/blood.V118.21.1636.1636

Published: 2011

Journal Articles

Chronic Lymphocytic Leukemia Shares a Common Cellular Origin with Regulatory B10 Cells

J. Brice Weinberg, MD, David J. DiLillo, PhD, Yohei Iwata, PhD, Takashi Matushita, PhD, Karen M. Matta, BS, Guglielmo M. Venturi, PhD, Giandomenico Russo, MD, PhD, Youwei Chen, MD, Jon P. Gockerman, MD, Joseph O. Moore, MD, Louis F. Diehl, MD, Alicia D. Volkheimer, MS, Daphne R. Friedman, M.D., Mark C Lanasa, MD, PhD, Russell P. Hall, MD, Thomas J. Tedder, PhD

Blood (2011) 118 (21): 286.

https://doi.org/10.1182/blood.V118.21.286.286

Published: 2011

Journal Articles

Prevalence of MBL Increases Over Time In Relatives of CLL Families,

Susan L Slager, PhD, Mark C Lanasa, MD, PhD, Sallie D. Allgood, MS, Sara J Achenbach, Aaron Norman, MS, Celine M Vachon, PhD, Lynn Goldin, PhD, Jose F. Leis, MD, PhD, Neil Kay, MD, J. Brice Weinberg, MD, Kari Rabe, MS, Timothy G. Call, MD, James R Cerhan, MD, PhD, Tait D. Shanafelt, MD, Neil E Caporaso, MD, Gerald E Marti, MD, PhD, Curtis A. Hanson, MD

Blood (2011) 118 (21): 3881.

https://doi.org/10.1182/blood.V118.21.3881.3881

Published: 2011

Journal Articles

Ofatumumab Based Chemoimmunotherapy (CIT) for Patients with Previously Untreated CLL,

Tait D. Shanafelt, MD, Mark C Lanasa, MD, PhD, Clive S. Zent, MD, Jose F. Leis, MD, PhD, Timothy G Call, MD, Betsy R. LaPlant, Han Tun, MD, Deborah A. Bowen, Diane F. Jelinek, Ph.D., Curtis A. Hanson, MD, Neil Kay, MD

Blood (2011) 118 (21): 3898.

https://doi.org/10.1182/blood.V118.21.3898.3898

Published: 2011

Journal Articles

Clinical Relevance of Immunophenotypic Characteristics in Chronic Lymphocytic Leukemia

Megan Diehl, MD, Evan L Kulbacki, MD, Gloria Broadwater, MS, Anand S. Lagoo, MD, PhD, J. Brice Weinberg, MD, Mark C Lanasa, MD, PhD

Blood (2011) 118 (21): 4604.

https://doi.org/10.1182/blood.V118.21.4604.4604

Published: 2011

Journal Articles

The Role of Surface Immunoglobulin Isotype in Chronic Lymphocytic Leukemia Disease Biology and Clinical Outcome

Danielle M. Brander, MD, Sallie D. Allgood, MS, Karen M. Bond, BS, J. Brice Weinberg, MD, Mark C Lanasa, MD, PhD

Blood (2011) 118 (21): 2850.

https://doi.org/10.1182/blood.V118.21.2850.2850

Published: 2011

Journal Articles

Pre-Clinical and Interim Results of a Phase II Trial of Perifosine In Patients with Relapsed or Refractory Chronic Lymphocytic Leukemia (CLL)

Daphne R. Friedman, MD, Patricia H. Davis, RN, BSN, OCN, Mark C. Lanasa, MD, PhD, Joseph O. Moore, MD, Jon P. Gockerman, MD, Taylor Nelson, BS, Karen M. Bond, BS, Ning Jiang, MD, Evan D. Davis, BS, Sallie D. Allgood, MS, Youwei Chen, MD, Peter Sportelli, J. Brice Weinberg, MD

Blood (2010) 116 (21): 1842.

https://doi.org/10.1182/blood.V116.21.1842.1842

Published: 2010

Journal Articles

Interim Analysis of EFC6663, a Multicenter Phase 2 Study of Alvocidib (flavopiridol), Demonstrates Clinical Responses Among Patients with Fludarabine Refractory CLL

Mark C Lanasa, MD, PhD, Leslie Andritsos, MD, Jennifer R Brown, MD, PhD, Janice Gabrilove, M.D., Federico Caligaris-Cappio, M.D., Richard Larson, M.D., Thomas J. Kipps, MD, PhD, Veronique Leblond, M.D., Donald Milligan, MD, FRCP, FRCPath, Ann Janssens, M.D., Nyla A. Heerema, Ph.D., Stephan Stilgenbauer, M.D., John C. Byrd, MD, Michael R. Grever, M.D.

Blood (2010) 116 (21): 58.

https://doi.org/10.1182/blood.V116.21.58.58

Published: 2010

Journal Articles

Investigation of CLL-Susceptibility Loci with Monoclonal B-Cell Lymphocytosis (MBL) Risk and Confirmation of Recently Reported CLL-Susceptibility Loci

Blood (2010) 116 (21): 2443.

https://doi.org/10.1182/blood.V116.21.2443.2443

Published: 2010

Journal Articles

First-In-Human Phase I Dose Escalation Study of a Humanized Anti-CD200 Antibody (Samalizumab) In Patients with Advanced Stage B Cell Chronic Lymphocytic Leukemia (B-CLL) or Multiple Myeloma (MM)

Daruka Mahadevan, MD, PhD, Mark C Lanasa, MD, PhD, Maria Whelden, RN, Susan J Faas, PhD, Terrie L Ulery, PhD, Anjli Kukreja, PhD, Lan Li, MS, MD, Camille L Bedrosian, MD, Leonard T Heffner, MD

Blood (2010) 116 (21): 2465.

https://doi.org/10.1182/blood.V116.21.2465.2465

Published: 2010

Journal Articles

Cenersen, An Antisense Inhibitor of p53, in Combination with Fludarabine, Cyclophosphamide, and Rituximab Shows Clinical Activity in High Risk CLL.

Mark C Lanasa, MD, PhD, Patricia H Davis, R.N, Michael Datto, M.D., Harry Cook, RPh, MBA, David A. Rizzieri, MD

Blood (2009) 114 (22): 3430.

https://doi.org/10.1182/blood.V114.22.3430.3430

Published: 2009

NARROW

Final Clinical Results with Laboratory Correlates in the Phase I Trial of Lenalidomide Plus Plerixafor in Previously Treated Chronic Lymphocytic Leukemia (CLL)

Molecular and Clinical Associations Between Vitamin D and Chronic Lymphocytic Leukemia

Next-Generation Sequencing Reveals Oncogenic Driver Mutations In Both Progressive and Non-Progressive Monoclonal B Lymphocytosis

First-In-Human Study Of AMG 319, a Highly Selective, Small Molecule Inhibitor Of PI3Kδ, In Adult Patients With Relapsed Or Refractory Lymphoid Malignancies

What Numbers Don't Say: Immunogenetic Evidence Shows That High-Count MBL Resembles Rai 0 CLL While Low-Count MBL Does Not.

The Relationship Between Socioeconomic Status and Clinical Outcomes in African Americans with Chronic Lymphocytic Leukemia

Comparison of the PI3K-δ Inhibitors TGR1202 and GS-1101 in Inducing Cytotoxicity and Inhibiting Phosphorylation of Akt in CLL Cells in Vitro

Circulating B Cell Clones in Familial Waldenström Macroglobulinemia.

Race As a Determinant of Disease Biology and Outcomes in Chronic Lymphocytic Leukemia

Phase 1 Study of TRU-016, An Anti-CD37 SMIP™ Protein in Relapsed and/or Refractory NHL Patients

Chronic Lymphocytic Leukemia Shares a Common Cellular Origin with Regulatory B10 Cells

Prevalence of MBL Increases Over Time In Relatives of CLL Families,

Ofatumumab Based Chemoimmunotherapy (CIT) for Patients with Previously Untreated CLL,

Clinical Relevance of Immunophenotypic Characteristics in Chronic Lymphocytic Leukemia

The Role of Surface Immunoglobulin Isotype in Chronic Lymphocytic Leukemia Disease Biology and Clinical Outcome

Pre-Clinical and Interim Results of a Phase II Trial of Perifosine In Patients with Relapsed or Refractory Chronic Lymphocytic Leukemia (CLL)

Interim Analysis of EFC6663, a Multicenter Phase 2 Study of Alvocidib (flavopiridol), Demonstrates Clinical Responses Among Patients with Fludarabine Refractory CLL

Investigation of CLL-Susceptibility Loci with Monoclonal B-Cell Lymphocytosis (MBL) Risk and Confirmation of Recently Reported CLL-Susceptibility Loci

First-In-Human Phase I Dose Escalation Study of a Humanized Anti-CD200 Antibody (Samalizumab) In Patients with Advanced Stage B Cell Chronic Lymphocytic Leukemia (B-CLL) or Multiple Myeloma (MM)

Cenersen, An Antisense Inhibitor of p53, in Combination with Fludarabine, Cyclophosphamide, and Rituximab Shows Clinical Activity in High Risk CLL.

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only